Prosecution Insights
Last updated: April 19, 2026
Application No. 17/939,785

METHOD FOR DIAGNOSING AGE-RELATED MACULAR DEGENERATION AND DEFINING LOCATION OF CHOROIDAL NEOVASCULARIZATION

Non-Final OA §103
Filed
Sep 07, 2022
Examiner
LU, ZHIYU
Art Unit
2665
Tech Center
2600 — Communications
Assignee
Taipei Veterans General Hospital
OA Round
3 (Non-Final)
49%
Grant Probability
Moderate
3-4
OA Rounds
3y 8m
To Grant
63%
With Interview

Examiner Intelligence

Grants 49% of resolved cases
49%
Career Allow Rate
374 granted / 759 resolved
-12.7% vs TC avg
Moderate +14% lift
Without
With
+13.9%
Interview Lift
resolved cases with interview
Typical timeline
3y 8m
Avg Prosecution
57 currently pending
Career history
816
Total Applications
across all art units

Statute-Specific Performance

§101
2.9%
-37.1% vs TC avg
§103
66.6%
+26.6% vs TC avg
§102
11.8%
-28.2% vs TC avg
§112
17.0%
-23.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 759 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 09/04/2025 has been entered. Response to Arguments Applicant’s arguments with respect to claim(s) 1, 5-9, 13-20 have been considered but are moot because the new ground of rejection does not rely on any reference applied in the prior rejection of record for any teaching or matter specifically challenged in the argument. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claim(s) 1, 5-9, 13-20 is/are rejected under 35 U.S.C. 103 as being unpatentable over Boyd et al. (US2021/0279874) in view of Lee et al. (US2022/0400943). To claim 1, Boyd teach a computer-implemented method for diagnosing age-related macular degeneration (AMD), the method (Figs. 4-6, paragraph 0057) consisting of: receiving one or more optical coherence tomography angiography (OCTA) image of a subject, wherein the one or more OCTA image each is an en-face OCT image (302 of Fig. 4, 402 of Fig. 5; paragraphs 0074, 0079); pre-processing the one or more OCTA image to obtain image data, comprising segmenting an image of deep capillary plexus (DCP) from the OCTA image to obtain image data comprising data of the DCP image (404 of Fig. 5; paragraph 0099, 0143); inputting the image data to a trained deep learning (DL) network (paragraphs 0007, 0210-0211, using deep learning network for image analysis; paragraph 0206, presence of the features in the subject's images may be determined using a classifier algorithm, which may be trained using the images and analysis from the cohorts), and wherein a plurality of training DCP images is used in training the DL network, each training DCP images being segmented from a training OCTA image (paragraphs 0124, 0126, 0206, 0209, 0224); generating, using the trained DL network, an output that characterizes the health of the subject with respect to AMD (paragraphs 0120, 0199-0205); and generating, based on the output, a diagnostic result comprising an indication of presence of neovascularization (NV) or presence of NV activity in the subject, an identification of a location of NV or NV activity or a feeder vessel supplying for an NV exudation in the one or more OCTA image (408 of Fig. 5; paragraphs 0006, 0103, 0219, 0221, 0241, 0245, 0275, 0341). But, Boyd do not expressly disclose wherein the DL network comprises one or more dense block layer. Lee teach a computer-implemented method for diagnosing age-related macular degeneration (AMD) (paragraph 0045) with en-face OCTA images (paragraphs 0040, 0045, 0052, 0082, 0086-0087, 0099), wherein dense convolutional neural network may be applied for image analysis (paragraphs 0057-0058). Therefore, it would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to incorporate teaching of Lee into the Boyd, in order to implement deep learning network by design preference. To claim 9, Boyd and Lee teach a system comprising one or more computers and one or more storage devices storing instructions that when executed by the one or more computers cause the one or more computers to perform operations (as explained in response to claim 1 above). To claim 17, Boyd and Lee teach one or more non-transitory computer-readable storage media encoded with instructions that when executed by one or more computers cause the one or more computers to perform operations (as explained in response to claim 1 above). To claims 5 and 13, Boyd and Lee teach claims 1 and 9. Boyd and Lee teach wherein the image data further comprises data of the image of outer retinal layer segmented from the OCTA image (Boyd, paragraphs 0224, 0393). To claims 6, 14 and 18, Boyd and Lee teach claims 1, 9 and 17. Boyd and Lee teach wherein a plurality of training OCTA images is used in training the DL network, each training OCTA images being pre-processed by segmenting training OCTA image to obtain at least one of an image of superficial capillary plexus, an image of deep capillary plexus, an image of outer retinal layer, and an image of choroid capillary layer (obvious as explained in response to claim 1 above, such as teachings in Boyd). To claims 7, 15 and 19, Boyd and Lee teach claims 6, 14 and 18. Boyd and Lee teach wherein the DL network is trained with image data of the image of superficial capillary plexus, the image of deep capillary plexus, the image of outer retinal layer, and the image of choroid capillary layer (obvious as explained in response to claim 1 above, such as teachings in Boyd). To claims 8, 16 and 20, Boyd and Lee teach claims 1, 9 and 17. Boyd and Lee teach wherein the classification of AMD classifies the subject as having no AMD, wet AMD or dry AMD (teaching in Boyd as explained in response to claim 1 above). Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to ZHIYU LU whose telephone number is (571)272-2837. The examiner can normally be reached Weekdays: 8:30AM - 5:00PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Stephen R Koziol can be reached at (408) 918-7630. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. ZHIYU . LU Primary Examiner Art Unit 2669 /ZHIYU LU/Primary Examiner, Art Unit 2665 November 18, 2025
Read full office action

Prosecution Timeline

Sep 07, 2022
Application Filed
Feb 07, 2025
Non-Final Rejection — §103
May 28, 2025
Response Filed
Jun 02, 2025
Final Rejection — §103
Sep 04, 2025
Request for Continued Examination
Sep 09, 2025
Response after Non-Final Action
Nov 18, 2025
Non-Final Rejection — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12601695
METHOD FOR MEASURING THE DETECTION SENSITIVITY OF AN X-RAY DEVICE
2y 5m to grant Granted Apr 14, 2026
Patent 12597268
METHOD AND DEVICE FOR DETERMINING LANE OF TRAVELING VEHICLE BY USING ARTIFICIAL NEURAL NETWORK, AND NAVIGATION DEVICE INCLUDING SAME
2y 5m to grant Granted Apr 07, 2026
Patent 12596187
METHOD, APPARATUS, AND SYSTEM FOR WIRELESS SENSING MEASUREMENT AND REPORTING
2y 5m to grant Granted Apr 07, 2026
Patent 12592052
INFORMATION PROCESSING DEVICE, AND INFORMATION PROCESSING METHOD
2y 5m to grant Granted Mar 31, 2026
Patent 12581142
APPROACHES FOR COMPRESSING AND DISTRIBUTING IMAGE DATA
2y 5m to grant Granted Mar 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
49%
Grant Probability
63%
With Interview (+13.9%)
3y 8m
Median Time to Grant
High
PTA Risk
Based on 759 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month